In line with this, iNOS deletion significantly reduced the activation of HSCs as confirmed by the reduced gene expression levels of both Tgfb and a-SMA (Acta2), suggesting that iNOS deficiency could regress the activation of HSC by interfering with the TGF-β pathway, protecting from liver fibrosis. The gene discussed is ACTA2; the disease is Hepatic fibrosis.